Sound implementation of human papillomavirus vaccination as a community-randomized trial

Therapy

Volumn 5, Issue 3, 2008, Pages 289-294

  Lehtinen, Matti ^a   French, K M ^b   Dillner, J ^c   Paavonen, Jorma ^d   Garnett, G ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Effectiveness; Herd immunity; Human papillomavirus; Phase IV trial; Public health; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER SCREENING; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CULTURAL FACTOR; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECONOMIC ASPECT; FINLAND; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MATHEMATICAL MODEL; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PATIENT SELECTION; POPULATION RESEARCH; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; RELIGION; SCANDINAVIA; SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VAGINA CANCER; VULVA CANCER; WART VIRUS;

EID: 44649125025     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.5.3.289     Document Type: Article

References (29)

1. Bosch FX, Castellsaque X, de Sanjose S: HPV and cervical cancer: screening or vaccination. Br. J. Cancer 98, 15-21 (2008).
2. Future II Study Group: Efficacy of a quadrivalent HPV types 8/11/16/18) L1 virus-like particle vaccine in the prevention of cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ: a randomized controlled trial. N. Engl. J. Med. 356, 1915-1927 (2007)
3. Paavonen J, Jenkins D, Bosch XF et al.: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. Lancet 369, 2161-2170 (2007).
4. Lehtinen M, Herrero R, Mayaud P et al.: Studies to assess long-term efficacy and effectiveness of HPV vaccination in developed and in developing countries. Vaccine S24, 233-241 (2006).
5. Geijersstam V, Kibur M, Wang Z et al.: Stability over time of serum antibody levels to human papillomavirus type 16. J. Infect. Dis. 177, 1710-1714 (1998).
6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Human papillomaviruses. IARC Monogr. Eval. Carcinog. Risks Hum. 90, 1-636 (2007).
7. Bottiger M, Forsgren M: Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine 14, 1538-1544 (1997).
8. Peltola H, Davidkin I, Paunio M et al.: Mumps and rubella elimination from Finland. JAMA 284, 2643-2647 (2000).
9. Barnabas R, Laukkanen P, Koskela P et al.: The epidemiology of HPV16 and cervical cancer in Finland and the potential of vaccination: mathematical modelling analyses. PLoS Med. 3(5), E138 (2006).
10. Lehtinen M, French K: Integration of the vaccine against human papillomaviruses into national vaccination programmes. Entre Nous 64, 12-13 (2007).
11. French KM, Barnabas R, Lehtinen M et al.: The impact of lowering the age of HPV vaccination and other vaccination strategies. Br. J. Cancer 96, 514-518 (2007).
12. Lehtinen M, Kaasila M, Pasanen K et al.: Seroprevalence ATLAS of HPV infections in Finland in the 1980's and 1990's. Int. J. Cancer 120, 2612-2619 (2006).
13. Lehtinen M, Paavonen J: Effectivenesss of human papillomavirus vaccination. Int. J. STD AIDS 14, 787-792 (2003).
14. Lehtinen M, Dillner J: Long-term follow-up of (community) randomized trials facilitates the implementation of human papillomavirus vaccination. HPV Today (2008) (In Press).
15. Brewer NT, Fazekas KI: Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev. Med. 45, 107-111 (2007).
16. Garnett GP: Role of herd immunity in determining the effect of vaccines against sexually transmitted diseases. J. Infect. Dis. 191, S97-S106 (2005).
17. Kane MA, Brooks A: New immunization initiatives and progress towards the global control of hepaptitis B. Curr. Opin. Infect. Dis. 15, 465-469 (2002).
18. Lipsitch M: Vaccination against colonizing bacteria with multiple serotypes. PNAS 94, 6571-6576 (1997).
19. Dagan R, Lipsitch M: Ecological effects of vaccines and antibiotics. In: The Pneumococcus. Tuomanen E, Mitchell TJ, Morrison DA, Spratt BG (Eds). ASM Press, Wahington DC, USA, 283-313 (2004).
20. Reingold A: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine in incidence of invasive penumocococcal disease. United States. MMWR Morb. Mortal. Wkly Rep. 54, 893-897 (2005).
21. Thomas KK, Hughes JP, Kuypers JM et al.: Concurrent and sequential acquisition of different genital human papillomavirus types. J. Infect. Dis. 182, 1097-1102 (2000).
22. Dillner L, Pagliusi S, Bray F et al.: Strengthening the prevention programs to eliminate cervical cancer in the Nordic countries. Acta Obstet. Gynecol. Scand. (2008) (In press).
23. Peto J, Gilham C, Felcther O, Matthews FE: The cervical cancer epidemic that screening has prevented in the UK. Lancet 364, 249-256 (2004).
24. Naucler P, Ryd W, Törnberg S et al.: Human paillomavirus and Papanicolau test to screen for cervical cancer. N. Engl. J. Med. 357, 1589-1597 (2007).
25. Hjalgrim H, Askling K, Rostgarr JK et al.: Characteristics of Hodgkin's lymphoma after infectioous mononucleosis. N. Engl. J. Med. 349, 1324-1329 (2003).
26. Sokal EM, Hopenbrouwers K, Vandermeulen C et al.: Recombinant gp350 vaccine for infectious mononucleosis. J. Infect. Dis. 196, 1749-1753 (2007).
27. Fisman D, Lipsitch M, Hook EW, Goldie SJ: Projection of future dimensions and cost of the Herpes simplex virus type 2 epidemic in the United States. Sex Transm. Dis. 29, 608-622 (2002).
28. Stanberry L, Spruance S, Cunningham AL et al.: Glycoprotein D vaccine to prevent genital herpes. N. Engl. J. Med. 347, 1652-1661 (2002).
29. Garnett G, Wadell H: Public health paradoxes and the epidemiology of human papillomavirus vaccination. J. Clin. Virol. 19, 101-112 (2000).